Aion Therapeutic Inc. operates in the health and wellness sector, focusing on drug manufacturing in the U.S. The company shows a concerning financial health score of 16/100, with a low current ratio of 0.19 indicating liquidity issues, and negative margins suggesting operational inefficiencies. While it has a gross margin of 39.2%, the negative EBITDA and net margins raise red flags about profitability. The low market cap of $2.49M and stagnant price reflect investor caution, highlighting the need for strategic improvements to enhance financial stability.
Loading financial metrics...
Company has $14K in cash but burned $386K last quarter. At this burn rate, only 0.0 quarters of runway remain without additional financing.
Gross profit margin declined from 39.9% to 20.3% year-over-year, suggesting pricing pressure or rising input costs are squeezing profitability.
Company posted a loss of $-6.6M over the last year, representing 451.2% of revenue.
Debt of $2.8M is 203.3x the company's cash position of $14K.
Operating cash flow has been negative for 3 consecutive quarters, burning $1.5M over the last year.
Exceptional revenue growth of 563.3% YoY demonstrates strong market demand and competitive positioning.
Operating margin expanded by 319.8pp, demonstrating strong operational leverage.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2025-Q1 (January 31, 2025)